Telephone: +44 (0)1223 750638
Greer Deal, Director of Global Regulatory Services (GRS), is delighted to be shortlisted for the TOPRA Futures Award especially because the Award is so relevant to GRS and the company strap line "driving innovation to market success".
19 May 2014 – Cambridge, UK. Global Regulatory Services (GRS) is delighted with the response their client, Babylon Partners, has received to the launch of the babylon health app. They launched the app to an audience of 5,000 at the Royal Albert Hall and were “humbled by the response”:
The Telegraph:"Set to revolutionise the healthcare system and eradicate waiting lists for subscribers."
Daily Express:“Ground-breaking…Babylon phone app puts a doctor in your pocket."
Global Regulatory Services (GRS) is featured in the May 2014 edition of the Cambridge Business Magazine. The article is entitled "Blame the breast implants" - eye catching to say the least!
Global Regulatory Services (GRS) is delighted to announce that on 25 April 2014 the company was awarded EU SME Status. So what does this actually mean? It means that our clients can take advantage of many incentives provided by Europe for SMEs developing innovative and new medicines for both human and veterinary patients. Crucially, there are a couple of very attractive fee discounts on offer:
As Global Regulatory Services (GRS) is a company focused on regulatory affairs and innovation, Greer is delighted to support the regulatory affairs profession as a TOPRA Awards Ambassador. TOPRA is “The Organisation for Professionals in Regulatory Affairs” with the vision of:
“Enabling and promoting excellence in the healthcare regulatory profession”
So what is the role of a TOPRA Awards Ambassador?
Greer Deal, Director of Global Regulatory Services, is delighted to be chairing this evening event in London on Thursday 20th March 2014.
FOR IMMEDIATE RELEASE
Bobby Deal, Managing Director
Global Regulatory Services (GRS)
Global House, Painters Lane, Sutton, Ely, Cambridgeshire CB6 2NS, UK
Phone: +44 (0)1223 750638
The 'must attend session' (11:15 to 12:15) at this year's Genesis Conference at the QEII Conference Centre, London.
So where do you go when your pipeline dries up and your products are going off patent? What ‘value add’ can you bring to your organisation? What areas could you, or should you, explore? To give you a clue, consider GSK exploring the possibility of developing products from Traditional Chinese Medicines (TCMs).
The Directors of GRS are deeply shocked and saddened by the sudden death of Andy King. Greer Deal knew Andy almost from the very beginning of her career in the life sciences over 20 years ago. She and Bobby Deal grew to know him more personally, however, when they officially launched Global Regulatory Services (GRS) in May 2008. He was incredibly supportive of GRS and more than willing to share his experiences and knowledge of business with Bobby and Greer. We had long-term plans to work with Andy but, whilst we were busy making plans, li
8 November 2013: The Directors of Global Regulatory Services (GRS) were directly involved in the €1.1m European Union (EU) research project examining Good Practice in Traditional Chinese Medicine Research (GP-TCM) in the Post-Genomic Era. Greer Deal was the Deputy Coordinator of The Seventh Work Package (Commercial R&D) of the FP7 EU-China GP-TCM Consortium. Both Directors were very actively involved in The Seventh Work Package (WP7). The aim of WP7 was:
|Copyright © 2014 GRS All Rights Reserved||
Global House, Painters Lane, Sutton, Ely,
Cambridgeshire, CB6 2NS, UK
Telephone: +44(0)1223 750638